With No­vavax vac­cine deal un­der its belt, SK Bio­science plots out March IPO on the Ko­re­an ex­change

It pays to be in the Covid-19 vac­cine man­u­fac­tur­ing busi­ness.

Short­ly af­ter it an­nounced an ex­pand­ed deal to pro­duce 40 mil­lion dos­es of No­vavax’s Covid-19 jab, SK Bio­science, an off­shoot of Ko­rea’s SK Group, un­veiled plans to launch an ini­tial pub­lic of­fer­ing on the Ko­re­an Ex­change in March with the goal of ex­pand­ing its con­tract man­u­fac­tur­ing busi­ness and build­ing on ex­ist­ing vac­cine de­vel­op­ment plat­forms.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER